Cortexyme touts success of periodontal disease drug candidate

By staff writers

July 23, 2021 -- Cortexyme touted new preclinical data for its atuzaginstat (COR388) drug candidate in treating periodontal disease at the 2021 International Association for Dental Research (IADR) virtual meeting.

The drug candidate was able to engage with and inhibit its target, lysine-gingipain from Porphyromonas gingivalis, within a biofilm and disrupt the biofilm integrity, the company said. In addition, a second-generation lysine-gingipain inhibitor, COR588, demonstrated biofilm penetration and target engagement similar to atuzaginstat, according to Cortexyme.

The company plans to begin phase I studies in the third quarter of 2021.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking